Advancing drug discovery using the power of the human genome

Human genetics plays an increasingly important role in drug development and population health. Here we review the history of human genetics in the context of accelerating the discovery of therapies, present examples of how human genetics evidence supports successful drug targets, and discuss how pol...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of pathology Vol. 254; no. 4; pp. 418 - 429
Main Authors Heilbron, Karl, Mozaffari, Sahar V, Vacic, Vladimir, Yue, Peng, Wang, Wei, Shi, Jingchunzi, Jubb, Adrian M, Pitts, Steven J, Wang, Xin
Format Journal Article
LanguageEnglish
Published Chichester, UK John Wiley & Sons, Ltd 01.07.2021
Wiley Subscription Services, Inc
Subjects
Biotechnology
direct‐to‐consumer
Drug development
Drug Discovery
Genetic diversity
Genetics
Genome, Human
Genomes
GWAS
human genetics
Humans
Invited Review
Invited Reviews
polygenic risk score
precision medicine
therapeutic discovery
Therapeutic targets
direct-to-consumer
human genetics
GWAS
therapeutic discovery
drug development
precision medicine
polygenic risk score
Online AccessGet full text

Cover

More Information
Summary:Human genetics plays an increasingly important role in drug development and population health. Here we review the history of human genetics in the context of accelerating the discovery of therapies, present examples of how human genetics evidence supports successful drug targets, and discuss how polygenic risk scores could be beneficial in various clinical settings. We highlight the value of direct‐to‐consumer platforms in the era of fast‐paced big data biotechnology, and how diverse genetic and health data can benefit society. © 2021 23andMe, Inc. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.
Bibliography:These authors contributed equally.
The copyright line for this article was changed on 21 April 2021 after original online publication.
Conflict of interest statement: All authors are current or former employees of 23andMe, Inc., and hold stock and/or stock options in 23andMe.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0022-3417
1096-9896
DOI:10.1002/path.5664